EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

IgA Vasculitis Across the Ages: Is It Time for a Precision Medicine Approach?

A Gage, R J Pepper, J Marro, A D Salama, L Oni iD

ACR Open Rheumatology · 2025-09 · 7 (9)

DOI: 10.1002/acr2.70083 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ACR Open Rheumatology, online erschienen am 12.09.2025. Verfasst von A Gage und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Kidney and Bladder Health, University College London, London, United Kingdom. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IgA vasculitis (IgAV; formerly Henoch‐Schönlein purpura) is a systemic small vessel vasculitis most commonly affecting the skin, gut, joints, and kidneys. Nephritis is the most concerning complication for all ages because it carries the risk of progression to irreversible end‐stage kidney failure. The multiorgan nature of the disease, variation in clinical presentation, and unpredictable disease course pose a substantial challenge to timely diagnosis, risk stratification, and a unified approach to management. Precision medicine is defined as a health care approach that uses genetic and molecular profiling alongside phenotypic and environmental data to generate insights to prevent or treat disease. This review article aims to provide an overview of IgAV using the latest literature to highlight three key areas in which precision medicine may have a role in advancing patient outcomes. These three areas are as follows: early phenotyping, risk stratification, and evidence‐based management. Due to the presence of nephritis bringing the greatest risk of morbidity and mortality for patients with this disease, kidney involvement forms the focal point of this review. Like other forms of glomerulonephritis, there are defined stages, from diagnosis to early signs of nephritis, histologically established nephritis, chronic kidney disease, and ultimately kidney failure. Advancing a disease for which there has been very little progress provides a huge opportunity to incorporate precision medicine from the outset to augment traditional monitoring and provide more rapid evidence generation. With transformative treatments on the horizon for IgA‐related glomerular diseases, improving patient outcomes to prevent kidney failure in IgAV is becoming a near reality. image

Autor:innen und Institutionen

  • Centre for Kidney and Bladder Health, University College London, London, United Kingdom.
  • University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom.
  • Centre for Kidney and Bladder Health, University College London and Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, and Department of Women's and Children's H…

ORCID-Profile: L Oni

Zitieren

APA

Gage, A., Pepper, R. J., Marro, J., Salama, A. D., & Oni, L. (2025). IgA Vasculitis Across the Ages: Is It Time for a Precision Medicine Approach?. ACR Open Rheumatology, 7(9). https://doi.org/10.1002/acr2.70083

Vancouver

Gage A, Pepper RJ, Marro J, Salama AD, Oni L. IgA Vasculitis Across the Ages: Is It Time for a Precision Medicine Approach?. ACR Open Rheumatology. 2025;7(9). doi:10.1002/acr2.70083

BibTeX
@article{Gage2025,
  author = {Gage, A and Pepper, R J and Marro, J and Salama, A D and Oni, L},
  title = {IgA Vasculitis Across the Ages: Is It Time for a Precision Medicine Approach?},
  journal = {ACR Open Rheumatology},
  year = {2025},
  volume = {7},
  number = {9},
  doi = {10.1002/acr2.70083}
}
Kostenlos starten →